摘要
目的评价恩替卡韦对不同时期乙肝肝硬化患者抗病毒的疗效。方法以2015年7月-2016年7月收治的50例乙肝肝硬化患者为研究对象,分为代偿期组30例和失代偿期组20例,2组均给予恩替卡韦治疗。结果代偿期组ALB、CHE、ALT、HBV-DNA、Child-Pugh评分检测值均优于失代偿期组,HBV-DNA转阴率及ALT复常率均明显高于失代偿期组,差异有统计学意义(P<0.05);代偿期组患者上消化道出血发生率为3.3%,明显低于失代偿期组的30%,差异有统计学意义(P<0.05)。结论恩替卡韦在失代偿期和代偿期乙型肝炎肝硬化的治疗过程中均具有重要价值,能够降低HBV-DNA病毒载量,显著改善肝功能,安全性好,可降低耐药率,是一种有效的抗病毒策略,特别是在代偿期阶段治疗效果更佳。
Objective To evaluate the efficacy of entecavir in the treatment of hepatitis B cirrhosis at different stages.Methods 50 patients with hepatitis B cirrhosis who were treated in July 2015-July 2016 were selected as study subjects,were divided into decompensated group of 30 cases and decompensated group of 20 cases,were given entecavir treatment.Results The ALB,CHE,ALT,HBV-DNA and Child-Pugh scores of decompensated group were better than those of decompensation group,HBV-DNA negative rate and ALT normalization rate were significantly higher than the decompensated group,the difference was significant（P0.05）. The incidence of upper gastrointestinal bleeding of decompensated group ofpatients was 3.3%,less than 30% of decompensated group,the difference was significant（P0.05）.Conclusion Entecavir in decompensated and decompensated patients with hepatitis B cirrhosis of the treatment process are of great value,can reduce the patient HBV-DNA viral load,significantly improve liver function,safety,and can reduce the resistance rate,is an effective antiviral strategy,especially in the compensatory phase of the treatmenteffect is better.
出处
《基层医学论坛》
2017年第13期1605-1607,共3页
The Medical Forum
